The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but the invasiveness of this procedure is its major drawback. Different non-invasive tests have been used to study changes in the stage of liver fibrosis in patients with chronic viral hepatitis treated with the second-generation of direct-acting antiviral agents: liver stiffness measurements (with transient elastography or acoustic radiation force impulse elastography) or different scores that use serum markers to calculate a fibrosis score. We prepared a literature review of the available data regarding the long-term evolution of liver fibrosis after the treatment with direct-acting antiviral agents for chronic viral hepatitis C.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Orasan, Olga H.; Ciulei, George; Coste, Sorina C.; Cibu, Bianca A.; Taut, Adela V. S; Tarmure, Simina F.; Pfingstgraf, Iulia O.; Alexescu, Teodora G.; Popovici, Ionela E.; Mureșan, Flaviu; Ovidiu, Fabian; Negrean, Vasile; and Cozma, Angela
"The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature,"
Journal of Mind and Medical Sciences: Vol. 6:
2, Article 5.
Available at: https://scholar.valpo.edu/jmms/vol6/iss2/5